

Clinical Efficacy of Telemedicine Compared with Face-to-face Clinic Visit on Smoking Cessation: A Multi-center, Open-label, Randomized Controlled, Non-inferiority Trial

Supplemental Files

Akihiro Nomura^{1,2,3}, Tomoyuki Tanigawa^{1,4}, Tomoyasu Muto⁵, Takefumi Oga⁶, Yasushi Fukushima⁷, Arihiro Kiyosue⁸, Masaki Miyazaki⁹, Eisuke Hida¹⁰, Kohta Satake^{1,5}

¹ CureApp Institute, Karuizawa, Japan

² Innovative Clinical Research Center, Kanazawa University (iCREK), Kanazawa, Japan

³ Department of Cardiology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

⁴ Graduate School of Public Health, St. Luke's International University, Tokyo, Japan

⁵ CureApp Inc., Tokyo, Japan

⁶ Shinjuku Research Park Clinic, Tokyo, Japan

⁷ Fukuwa Clinic, Tokyo, Japan

⁸ Tokyo-eki Center Building Clinic, Tokyo, Japan

⁹ Miyazaki RC Clinic, Tokyo, Japan

¹⁰ Department of Biostatistics and Data Science, Osaka University Graduate School of Medicine, Osaka, Japan

Corresponding author:

Akihiro Nomura, MD, PhD

Innovative Clinical Research Center, Kanazawa University (iCREK)


Kanazawa, Japan

Phone number: +81-76-265-2049


E-mail: anomura@med.kanazawa-u.ac.jp

Supplemental figure 1. Absolute difference of CAR at weeks 9–12, 95% confidence interval and comparison to the pre-specified non-inferior margin.

The absolute difference of CAR at weeks 9–12 between the telemedicine and control groups was 2.1% (95% CI: -12.8–17.0). The lower limit of the 95% confidence interval of -12.8% was greater than the pre-specified limit of -15%.



Supplemental figure 2. Efficacy of telemedicine on the continuous abstinence rates at weeks 9–12 by subgroup.



Abbreviations: BMI, body mass index; CI, confidence interval; FTND, Fagerström Test for Nicotine Dependence; KTSND, Kano Test for Social Nicotine Dependence; se, standard error; and TDS, Tobacco Dependence Screener.

Supplemental table 1. Program adherence rates by session.

	Total N	Weeks 2		Weeks 4		Weeks 8		Weeks 12		Weeks 24	
Standard care	57	55	96%	55	96%	55	96%	54	95%	55	96%
Telemedicine	58	57	98%	57	98%	57	98%	57	98%	57	98%

Supplemental table 2. List of adverse events.

	Total N = 115	Telemedicine n = 58	Standard care n = 57
At least one AE	25 (22)	12 (21)	13 (23)
Mild	3 (3)	2 (3)	1 (2)
Moderate	22 (19)	10 (17)	12 (21)
Severe	0	0	0
At least one AE related to trial device	0	0	0
At least one AE related to smoking cessation medication	22 (19)	10 (17)	12 (21)
At least one SAE	0	0	0

Values are n (%).

Abbreviations: AE, adverse event; and SAE, serious adverse event.

Supplemental table 3. Evolution of scores by MPSS, FTCQ-12, KTSND, and NDCS.

	Baseline (IQR)	2 weeks	4 weeks	8 weeks	12 weeks	24 weeks
MPSS						
Depressed						
Telemedicine	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–1)
Control	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)
Irritable						
Telemedicine	2 (1–2)	2 (1–3)	2 (1–3)	2 (1–2)	2 (1–2)	1* (1–2)
Control	2 (1–2)	2 (1–3)	2 (1–2)	2 (1–2)	1 (1–2)	1 (1–2)
Restless						
Telemedicine	1 (1–2)	2 (1–2)	1 (1–2)	1 (1–2)	1 (1–2)	1 (1–1)
Control	1 (1–2)	2 (1–2)	1 (1–2)	1 (1–2)	1 (1–1)	1 (1–2)
Hungry						
Telemedicine	3 (2–3)	2 (1–3)	2 (1–3)	2 (2–3)	3 (2–3)	2 (1–3)
Control	2 (2–3)	2 (1–3)	2 (1–3)	2 (2–3)	2 (1–3)	2 (1–3)
Poor concentration						
Telemedicine	2 (1–2)	2 (1–2)	2 (1–2)	2 (1–2)	1 (1–2)	1 (1–2)
Control	2 (1–2)	2 (1–2)	1 (1–2)	2 (1–2)	1 (1–2)	1 (1–2)
Time spent with urges						
Telemedicine	2 (2–3)	2 (2–3)	2 (1–2)	1 (1–2)	1* (1–2)	1* (0–2)
Control	2 (2–3)	2 (2–3)	2 (1–2)	2 (1–2)	1* (1–2)	1* (0–2)
Strength of urges						
Telemedicine	2 (1–3)	2 (1–2)	2 (0–2)	1 (0–1)	1* (0–1)	0* (0–1)
Control	2 (1–3)	2 (1–3)	2 (0–2)	1 (0–1)	1* (0–1)	1* (0–1)
FTCQ-12						
Emotionality						
Telemedicine	2.8 (2.1–3.8)	2.0 (1.5–2.8)	1.5 (1.0–2.4)	1.3 (1.0–2.0)	1.0* (1.0–1.8)	1.0* (1.0–1.8)
Control	3.0 (2.0–4.0)	2.5 (1.5–3.3)	1.8 (1.0–3.0)	1.3 (1.0–2.3)	1.0* (1.0–2.0)	1.3* (1.0–2.5)
Expectancy						
Telemedicine	5.0 (4.1–5.7)	3.7 (3.0–4.7)	3.3 (2.3–4.0)	2.7 (1.7–3.5)	2.0* (1.3–3.0)	2.3* (1.0–3.0)
Control	4.7 (4.0–6.0)	4.0 (3.0–4.7)	3.3 (2.3–4.3)	2.7 (1.7–3.7)	2.0* (1.3–3.7)	2.3* (1.7–3.3)
Compulsivity						
Telemedicine	3.3 (2.3–4.3)	2.0 (1.3–3.0)	2.0 (1.3–2.8)	1.7 (1.0–3.0)	1.7* (1.0–3.0)	1.3* (1.0–2.7)
Control	3.7 (2.3–4.0)	2.3 (1.7–3.0)	2.0 (1.3–3.0)	2.0 (1.0–3.0)	1.7* (1.0–2.7)	1.3* (1.0–3.0)
Purposefulness						

Telemedicine	5.5 (4.6–6.0)	4.5 (3.5–5.5)	4.0 (2.3–5.0)	2.5 (1.5–4.0)	2.0* (1.5–4.0)	1.5* (1.0–4.5)
Control	5.5 (4.5–6.0)	4.5 (4.0–5.5)	3.5 (1.5–5.5)	3.0 (1.5–4.5)	2.0* (1.0–3.5)	3.0* (1.0–4.3)
General Craving Score						
Telemedicine	3.8 (3.4–4.4)	2.9 (2.5–3.6)	2.6 (2.0–3.2)	2.1 (1.6–2.7)	2.0* (1.5–2.4)	1.8* (1.3–2.4)
Control	3.8 (3.2–4.6)	3.3 (2.7–3.6)	2.7 (1.8–3.3)	2.5 (1.6–3.1)	1.8* (1.4–2.6)	2.2* (1.4–2.8)
KTSND						
Telemedicine	17 (16–20)	-	-	12 (11–16)	11*(8–14)	11*(7–14)
Control	18 (15–21)	-	-	15 (12–18)	13*(9–17)	11*(7–16)
NDCS						
Telemedicine	12 (11–14)	-	-	-	6* (3–8)	6* (1–9)
Control	12 (10–14)	-	-	-	6* (4–9)	6* (3–8)

Abbreviations: FTCQ-12, 12-item French version of the Tobacco Craving Questionnaire; IQR, interquartile range; KTSND, Kano Test for Social Nicotine Dependence; MPSS, Mood and Physical Symptoms Scale; and NDCS, Nicotine Dependence Cognition Scale.

*P <0.001 by the Wilcoxon signed-rank test compared with the baseline in each group.